he continuing emergence of immune-evasive variants of SARS-CoV-2 virus represents a major challenge in controlling COVID-19 pandemic disease. Researchers from Stanford University have tested the immunogenicity and protective effect of the receptor binding domain (RBD)-I53-50 AS03-adjuvanted nanoparticle vaccine in nonhuman primates.
In the search for novel antibacterial agents, some targets have been engaged to kill Gram-positive but not Gram-negative organisms, due to lack of accumulation of proposed agents.
Janssen and Johnson & Johnson have divulged dihydropyrimidine derivatives reported to be useful for the treatment of hepatitis B virus (HBV) infections.
Hansoh Pharmaceutical's Hansoh (Shanghai) Healthtech subsidiary has entered into an exclusive licensing and codevelopment agreement with the Global Health Drug Discovery Institute (GHDDI; Beijing Huayi Health Drug Discovery Institute) for exclusive worldwide rights to develop, manufacture and commercialize GDI-4405, an oral small-molecule SARS-CoV-2 3CL protease inhibitor.
A factor involved in the apoptosis cascade, caspase-6, has been identified as a target for interfering with the replication of coronaviruses in work by The University of Hong Kong scientists and their collaborators.
Griffith University has presented new compounds reported to be useful for the treatment of respiratory syncytial virus (RSV), influenza A, influenza B, influenza C and parainfluenza virus infections.
The University of Michigan, the University of Illinois and the Penn State Research Foundation have presented rifamycin derivatives acting as RNA polymerase (bacterial) inhibitors reported to be useful for the treatment of tuberculosis.
RSS